Indivior submits US FDA application for opioid-addiction treatment
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
Essential IR Insights Newsletter - Summer July-August 2023
Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits
Indivior PLC submitted a new drug application to the U.S. FDA for its product candidate, RBP-6000, following a successful phase 3 study.
RBP-6000 is an investigational, once-monthly injectable form of buprenorphine to treat moderate to severe opioid use disorder.
